Advertisement

Teva offers $40 billion for Mylan

Generic drugmaker Teva Pharmaceutical is offering $82 a share, or $40 billion, for its smaller rival Mylan, in an alternative to Mylan's deal to buy Perrigo. Bobbi Rebell reports.